Immuron stock rockets after funding by U.S. DoD of new research agreement
Shares of Immuron Ltd. IMRN, +46.18% rocketed 49.6% in active premarket trading Wednesday, after the Australia-based biopharmaceutical company said it received an award of AUD$6.2 million ($4.5 million) from the U.S. Department of Defense to evaluate Travelan for military use. Trading...
The Company
www.immuron.com.au
Immuron Limited is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies that we believe can address significant unmet medical needs. The company was...
themarketherald.com.au
Immuron's (IMC) share price has more than doubled on the news a drug used in its traveller's diarrhoea formulation neutralises activity aginst the COVID-19 virus
The company tested its IMM-124E treatment and has seen antiviral activity against SARS-CoV-2, the virus that causes COVID-19
IMM-124E is used to manufacture the...
Immuron’s commercially available products found to neutralise COVID-19 during in vitro research
smallcaps.com.au
Immuron’s commercially available products found to neutralise COVID-19 during in vitro research
By
Lorna Nicholas -
July 21, 2020
Immuron ASX IMC NASDAQ IMRN SARS-CoV-2 COVID-19 antiviral studies Travelan Protectyn
Immuron plans to investigate the...
NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC
-Two human phase II clinical trials to be conducted in 2021
-One trial will focus on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis
-The second trial will focus on ETEC...
US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea
Key Points
NMRC requests Pre-IND meeting with FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC
Two human phase II clinical trials to be conducted in 2021
One trial will focus on the ability of the...
